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A metabolic switch toward lipid use in glycolytic
muscle is an early pathologic event in a mouse
model of amyotrophic lateral sclerosis
Lavinia Palamiuc1,2, Anna Schlagowski3,4, Shyuan T Ngo5,6, Aurelia Vernay1,2, Sylvie Dirrig-Grosch1,2,
Alexandre Henriques1,2, Anne-Laurence Boutillier7, Joffrey Zoll3,4, Andoni Echaniz-Laguna1,2,8,
Jean-Philippe Loeffler1,2,* & Frédérique René1,2,**
Abstract
Amyotrophic lateral sclerosis (ALS) is the most common fatal motor
neuron disease in adults. Numerous studies indicate that ALS is a
systemic disease that affects whole body physiology and metabolic
homeostasis. Using a mouse model of the disease (SOD1G86R), we
investigated muscle physiology and motor behavior with respect
to muscle metabolic capacity. We found that at 65 days of age, an
age described as asymptomatic, SOD1G86R mice presented with
improved endurance capacity associated with an early inhibition
in the capacity for glycolytic muscle to use glucose as a source of
energy and a switch in fuel preference toward lipids. Indeed, in
glycolytic muscles we showed progressive induction of pyruvate
dehydrogenase kinase 4 expression. Phosphofructokinase 1 was
inhibited, and the expression of lipid handling molecules was
increased. This mechanism represents a chronic pathologic alter-
ation in muscle metabolism that is exacerbated with disease
progression. Further, inhibition of pyruvate dehydrogenase kinase 4
activity with dichloroacetate delayed symptom onset while
improving mitochondrial dysfunction and ameliorating muscle
denervation. In this study, we provide the first molecular basis for
the particular sensitivity of glycolytic muscles to ALS pathology.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common adult
motor neuron disease. Although historically defined as an age-
related neurodegenerative disease specifically affecting upper and
lower motor neurons, 145 years of research has now identified for
ALS to be unquestionably more complex than initially described. In
recent years, several non-neuronal cells including microglia (Boille´e
et al, 2006), astrocytes (Yamanaka et al, 2008), and skeletal muscle
(Wong & Martin, 2010) have been proposed to influence the course
of the disease. Moreover, mutations in an increasing number of
genes have been associated with familial and sporadic forms of ALS
(Chen et al, 2013). In accordance with this genetic heterogeneity,
ALS has recently been redefined as a ‘syndrome’, regrouping
complex and diverse pathophysiological and clinical manifestations
that transgress the motor system (Andersen & Al-Chalabi, 2011;
Hardiman et al, 2011).
Numerous studies indicate that ALS is a systemic disease that
affects whole body physiology and energy homeostasis. In 2001, a
systematic analysis of energy expenditure rates in a population of
sporadic ALS patients revealed that two-thirds of these patients were
hypermetabolic (Desport et al, 2001). These observations were
further confirmed and extended to familial ALS cases in follow-up
reports (Desport et al, 2005; Bouteloup et al, 2009). ALS patients as
well as mouse models of ALS present with weight loss and reduced
fat mass, altered glucose and lipid handling, and increased resting
energy expenditure (Dupuis et al, 2011). In mice, reduced lipid
stores and increased resting energy expenditure precede motor
symptoms (Dupuis et al, 2004). Interestingly, the burden of these
metabolic alterations appears to affect the neurodegenerative
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process. Indeed, metabolic alterations correlate with duration of
survival, and clinical data suggest that an imbalance in energy
metabolism has a negative impact on the pathogenic process
(Desport et al, 1999; Jawaid et al, 2010). Moreover, increased
dietary lipid content offers neuroprotection and extends survival in
mouse models of ALS (Dupuis et al, 2004; Mattson et al, 2007),
while restricting calorie intake exacerbated motor symptoms in ALS
mice (Pedersen & Mattson, 1999). Although the origin of metabolic
dysfunction in ALS remains unclear, many of the metabolic modifi-
cations observed at the systemic level in ALS patients and related
mouse models imply that skeletal muscle contributes to ALS
progression.
At rest, skeletal muscle accounts for 20–30% of the total energy
expenditure. Given that skeletal muscle plays a critical role in
maintaining metabolic homeostasis, altered energy balance in this
tissue over extended periods of time may represent a risk factor
for the development of ALS. Interestingly, thorough mapping of
neuromuscular junction (NMJ) denervation patterns in the
SOD1G93A mouse model of ALS revealed increased susceptibility of
glycolytic fibers to undergo denervation. The loss of fast fatigable
motor units composed of large motor neurons innervating type IIb
fast glycolytic fibers before any apparent motor symptoms (Frey
et al, 2000; Hegedus et al, 2008) suggests that the metabolic signa-
ture of glycolytic fibers may predispose them to NMJ dismantle-
ment, one of the first pathologic events in the course of the
disease (Fischer et al, 2004). Indeed, we have previously shown
that promotion of muscle-specific hypermetabolism is sufficient to
induce some hallmarks of ALS including destruction of the neuro-
muscular junction (NMJ) and the death of motor neurons (Dupuis
et al, 2009). Collectively, these data suggest that metabolic
changes in skeletal muscle could contribute to early destabilization
of the NMJ in ALS.
In this study, we investigated early muscle metabolic alterations
that might account for the metabolic imbalance and early NMJ
denervation observed in SOD1G86R mice. We report an early alter-
ation in muscle metabolic homeostasis in SOD1G86R mice. The
switch toward lipid use in glycolytic muscle precedes NMJ denerva-
tion detected by EMG and the increase in expression of denervation
markers. By administering dichloroacetate (DCA) to SOD1G86R mice,
we reversed metabolic imbalance, improved metabolic function,
and normalized the expression of denervation markers in SOD1G86R
mice. Our results reveal an early metabolic pathology in skeletal
muscle that contributes to the severity of the disease and adds new
insight into the already complex ALS syndrome.
Results
Asymptomatic SOD1G86R mice have increased aerobic capacity
During ALS disease progression, a progressive shift in skeletal
muscle fiber subtype from fast twitch to slow twitch would presum-
ably result in a concomitant shift toward more oxidative metabolism
(Dengler et al, 1990; Frey et al, 2000; Pun et al, 2006; Deforges
et al, 2009). Thus, we aimed to determine whether SOD1G86R mice
would have improved capacity to support endurance exercise. We
compared anaerobic versus aerobic capacities of 65-day-old asymp-
tomatic SOD1G86R mice using two exercise paradigms on a treadmill
apparatus: an intense anaerobic exercise that recruits glycolytic
fast-twitch fibers (Fig 1A–C) and a low-intensity endurance exercise
that mobilizes slow-twitch oxidative muscle fibers (Fig 1D–F). As
shown in Fig 1A, when treadmill speed was progressively increased
in the intense anaerobic exercise paradigm, 65-day-old SOD1G86R
mice had significantly poorer performance than their WT litter-
mates; SOD1G86R mice ran on the treadmill for an average of
13.50 min (median at 14.33), while their WT littermates spent an
average of 15.78 min (median at 15.50) on the treadmill (Fig 1B).
Accordingly, SOD1G86R mice ran a total distance that was 17.6%
shorter than the distance covered by their WT littermates (Fig 1C).
By contrast, when challenged with a moderate exercise paradigm
that is representative of an endurance workout (Fig 1D–F),
SOD1G86R mice proved to have significantly greater endurance than
their WT littermates (Fig 1D). In response to moderate exercise,
SOD1G86R mice ran an average of 67.34 min (median at 65.43)
before reaching exhaustion, while their WT littermates ran an aver-
age of 46.10 min (median at 59.33) prior to exhaustion (Fig 1D).
Indeed, the resistance of SOD1G86R mice to reach exhaustion when
subjected to this exercise paradigm resulted in them running a total
distance that was 36% greater than the distance covered by their
WT littermates (Fig 1E).
Given that skeletal muscle possesses the capacity to adapt meta-
bolically to physical and functional challenges (Constable et al,
1987; Bassel-Duby & Olson, 2006), the enhanced aerobic capacity
and poor anaerobic capacity of SOD1G86R mice might occur as a
consequence of muscle denervation. In this study, we assessed the
expression of AChRa and AChRc, two subunits of the nicotinic
acetylcholine receptor, and Musk, a muscle-specific kinase, all of
which are rapidly overexpressed after denervation or when muscle
electrical activity is absent (Duclert & Changeux, 1995; Valenzuela
et al, 1995). However, at 65 days of age SOD1G86R mice did not
present with any sign of denervation regardless of the metabolic
capacity of muscle; muscle grip strength was comparable to that of
WT littermates (Fig 2A), EMG profiles were normal (Fig 2B), and
the mRNA expression of molecular markers of denervation (Fig 2C)
and atrophy (Fig 2D) in glycolytic tibialis anterior (TA) or oxidative
soleus muscles was similar to WT levels. By contrast, at 105 days
when SOD1G86R mice are paralyzed and grip strength is decreased
(Fig 2A), all SOD1G86R presented with increased spontaneous activ-
ity on their EMG profiles (Fig 2B). Moreover, induction of denerva-
tion and atrophy markers was more pronounced in the TA than in
the soleus (Fig 2C and D). These data support previous observations
that in ALS, glycolytic muscles are more severely affected by disease
pathology than oxidative muscles (Dengler et al, 1990; Frey et al,
2000; Pun et al, 2006). We therefore focused our subsequent analy-
sis on the glycolytic TA.
Muscle glucose metabolism is inhibited in asymptomatic
SOD1G86R mice
Glycolysis is the only metabolic pathway that provides a source of
high-energy substrates for anaerobic exercise. Given that impaired
glycolytic performance in SOD1G86R mice cannot be explained by
denervation or atrophy, we hypothesized that reduced anaerobic
performance was due to defective glucose utilization. In order to
verify whether glucose metabolism is altered in SOD1G86R mice, we
first analyzed their response to glucose and insulin. The glucose
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tolerance test (Supplementary Fig S1A) showed that at 65 days,
SOD1G86R mice presented with higher blood glucose at 30 and
45 min when compared to WT littermates, suggesting that initial
glucose clearance is delayed in SOD1G86R mice. However, after
120 min blood glucose levels were similar between WT and
SOD1G86R mice, suggesting that there may be increased glucose
uptake between 30 and 120 min in SOD1G86R mice. The response to
insulin was also delayed in SOD1G86R mice when compared to WT
littermates (Supplementary Fig S1B). These data show an alteration
in glucose handling in SOD1G86R mice at the asymptomatic stage of
disease.
To determine whether altered glucose handling occurred at
the level of skeletal muscle, we assessed the activity of
phosphofructokinase 1 (PFK1), the rate-limiting enzyme of
glycolysis, in TA cytosolic homogenates (Fig 3A). When compared
to WT littermates, SOD1G86R mice had a significant 23% reduction in
PFK1 enzymatic activity at 65 days of age. By the end stage of
disease (105 days of age), PFK1 activity was reduced by 88.8% in
SOD1G86R mice when compared to WT littermates. This was accom-
panied by a 5-fold down-regulation in the expression of Pfk1 mRNA
in SOD1G86R mice (Supplementary Fig S1C). Interestingly, a 4-fold
down-regulation in the expression of Pfk1 mRNA was also observed
A
D
B C
E F
Intense exercise – incremental speed
Moderate exercise – constant speed
Figure 1. 65-day-old SOD1G86R mice have improved performance during endurance exercise.
A–F (A–C) Exercise performance on a treadmill apparatus using an intense exercise (incremental speed paradigm) that relies solely on anaerobic metabolism. (D–F)
Exercise performance on a treadmill apparatus using a moderate exercise (constant sub-maximal speed) that relies on the recruitment of aerobic metabolism and
that is representative of endurance exercise. (A, D) Kaplan–Meier curves representing values corresponding to the percentage of mice still running at a given
time point. (B, E) Median values of the time that mice ran are represented in the min to max graphical representation; 15.5 min for wild-type (WT) and 14.33 min
for SOD1G86R in (B); 59.33 min for WT and 65.43 min for SOD1G86R in (E). (C, F) Mean distance run  SEM by WT and SOD1G86R mice in (C) and by WT and SOD1G86R
mice in (F).
Data information: G86R versus WT, P = 0.017 in (A), **P = 0.0078 in (B), **P = 0.008 in (C) and P = 0.036 in (D) (Mantel–Cox test), **P = 0.0078 in (E), and **P = 0.0061 in (F)
(Student’s t-test), n = 10 and 13 for WT and SOD1G86R, respectively.
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Age (weeks) Age (weeks)
A B
C Denervation markers
Tibialis anterior
Soleus
65 days 105 days
65 days 105 days
D Atrophy markers
Tibialis anterior
Soleus
65 days 105 days
65 days 105 days
Figure 2.
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in SOD1G93A mice, another ALS mouse model, at the end stage of
disease (Supplementary Fig S2B).
Glycolysis is regulated by a number of upstream and down-
stream components. Pyruvate is the end product of glycolysis and a
downstream component in the glycolytic pathway that inhibits
muscle PFK1 while glycogen synthase is a key enzyme that converts
glucose to glycogen. Thus, we assessed pyruvate levels, glycogen
synthase activity, and glycogen accumulation in the TA of
SOD1G86R mice and WT littermates at the asymptomatic and symp-
tomatic stages of disease. Pyruvate was 1.7-fold more concentrated
in 65-day-old SOD1G86R mice than in age-matched WT littermates
(Fig 3B). By 105 days of age, symptomatic SOD1G86R mice had a
significant reduction in pyruvate levels when compared to WT
littermates. Changes in the expression of pyruvate levels in
SOD1G86R mice occurred concurrently with altered activity of
glycogen synthase and altered glycogen accumulation. At 65 days
of age, SOD1G86R mice had decreased phosphorylation of glycogen
synthase (Fig 3C) and a corresponding increase in glycogen accu-
mulation (Fig 3D). By contrast, glycogen synthase phosphorylation
in SOD1G86R mice at 105 days of age was dramatically increased,
indicating the inhibition of its activity. The increased synthesis of
glycogen and its subsequent accumulation was quantified in trans-
verse sections of TA stained by periodic acid-Schiff (PAS)
(Fig 3D).
Pyruvate dehydrogenase kinase 4 up-regulation in glycolytic
muscle tissue is an early event
In skeletal muscle, pyruvate levels are primarily governed by pyru-
vate dehydrogenase complex (PDH) activity, which itself is inhib-
ited when phosphorylated by pyruvate dehydrogenase kinase 4
(PDK4). Thus, we assessed the expression levels of Pdk4 mRNA
by RT–qPCR. As shown in Fig 4A, at 65 days of age SOD1G86R
mice had a 2.2-fold increase in Pdk4 mRNA levels in TA when
compared to WT mice (Fig 4A). At the end stage of disease, Pdk4
mRNA expression was 8.9-fold higher in SOD1G86R mice when
compared to age-matched WT littermates. Noticeably, in the soleus
muscle of SOD1G86R mice, Pdk4 expression was comparable to that
of WT mice at 65 and 105 days of age (Supplementary Fig S3). By
contrast, Pdk2 transcript levels were similar between SOD1G86R
mice and WT littermates in TA and in soleus at 65 days of age,
but decreased by 2- and 0.3-fold in these respective muscles at
105 days of age (Fig 4A and Supplementary Fig S3). In SOD1G93A
mice (Supplementary Fig S2C and D), Pdk4 mRNA levels were
transiently increased by 50% at onset when mice develop signs of
hindlimb weakness, prior to returning to control levels at end
stage, while Pdk2 transcript levels were decreased by 50% from
onset to end stage when compared to WT littermates. In muscle
biopsies of definite ALS patients (Supplementary Fig S4), Pdk4
mRNA levels were increased 3-fold while Pdk2 mRNA levels
remained unchanged when compared to controls.
PDK4 expression is stimulated by various parameters including
skeletal muscle denervation, increased fatty acid (FA) use through
b-oxidation (Jeong et al, 2012), and transcription factors peroxi-
some proliferator-activated receptors b/d (PPARb/d) and forkhead
Box O1A (FOXO1).
NMJ dysfunction could participate in Pdk4 up-regulation
To determine whether denervation could be responsible for the
induction of Pdk4 expression seen in ALS mice and patients, we
used two complementary paradigms: a mild sciatic nerve crush that
induces a transient denervation, and a chronic denervation obtained
by sciatic nerve axotomy in WT mice. After sciatic nerve crush,
mice were observed for paralysis of the ipsilateral hindlimb, sacri-
ficed at various times (3 h to 8 weeks post-crush) and gene expres-
sion levels were measured in TA ipsilateral and contralateral to the
site of nerve crush. Supplementary Fig S5A shows the rapid loss of
the innervated NMJs starting from 1 day post-crush (DPC) to 5 DPC
and the progressive reinnervation already visible after 1 week post-
crush (WPC). As shown in Supplementary Fig S5B, the expression
of AChRa started to increase (2-fold induction) at 1 DPC, reached a
plateau between 3 DPC and 1 WPC with a 40- to 60-fold induction,
and then returned to control level by weeks 4 and 8. Pdk4 mRNA
levels were increased by 50% during the early phase of synaptic
destabilization with no significant changes on Pdk2 mRNA levels
(Supplementary Fig S5B). By contrast, Pparb/d and Foxo1 (Supple-
mentary Fig S5B) expression were rapidly and transiently stimulated
by 2-fold. After sciatic nerve axotomy (Supplementary Fig S6),
AChRa, Pdk4, Pparb/d, and Foxo1 were still induced after 2 weeks
of chronic denervation in both TA and soleus muscle while Pdk2
mRNA levels were decreased. Collectively, these results show that
Figure 2. Decreased grip strength, increased denervation, and increased expression of denervation and atrophy markers throughout disease progression in
SOD1G86R mice.
A Grip test was performed to measure mouse muscle strength at different time points during disease progression. Graph represents the mean of percentage from
initial force measured at 11 weeks  SEM. At 13 weeks, *P = 0.03; at 14 weeks, P = 0.06; at 15 weeks, *P = 0.04 (n = 8 for WT and SOD1G86R, respectively, at
11–15 weeks, two-way ANOVA followed by Fisher’s LSD post hoc test).
B Electromyography (EMG) recordings were performed weekly during disease development, starting from 9 weeks of age. Spontaneous electrical activity was considered
as positive EMG only for peak-to-peak amplitudes > 50 lV. Left: The percentage of mice presenting with positive EMG in each age group are represented. Right:
Representative examples of negative (EMG) and positive (EMG+) electromyography profiles (n = 10 for WT and SOD1G86R, respectively, at 9–13 weeks and n = 8 and
7 for WT and SOD1G86R, respectively, at 15 weeks).
C Relative mRNA levels of denervation markers AChR (subunits a and c) and MuSK were evaluated by qPCR at the indicated ages (65 and 105 days) in tibialis anterior
(upper panels) and soleus (lower panels) of WT and SOD1G86R mice. Graphs represent mean fold change  SEM from age-matched WT (n > 5). ***P-values versus WT:
< 0.0001 for AChRa, AChRc, and MuSK in tibialis anterior; and **P-values versus WT: 0.001 for AChRa, and ***P-values versus WT: 0.0007 for AChRc, 0.0002 for MuSK in
soleus (n=7 and 8 for WT and SOD1G86R, respectively, at 65 days; n = 5 and 6 for WT and SOD1G86R, respectively, at 105 days; two-way ANOVA followed by Fisher’s LSD
post hoc test).
D Relative mRNA levels of muscle atrophy markers MuRF1 and Atg-1 were measured by qPCR at the indicated ages (65 and 105 days) in tibialis anterior (upper panels)
and soleus (lower panels). Graphs represent mean fold change  SEM from age-matched WT. ***P-values versus WT: < 0.0001 for MuRF1 and Atg-1 in tibialis
anterior; and **P-values versus WT: 0.007 for MuRF1 and P = 0.006 for Atg-1 in soleus (n = 7 and 8 for WT and SOD1G86R, respectively, at 65 days, n = 5 and 6 for WT
and SOD1G86R, respectively, at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test).
◀
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Figure 3. Phosphofructokinase 1 is inhibited in glycolytic muscle and glucose is rerouted toward glycogen stores.
A Enzymatic activity of phosphofructokinase in whole tibialis anterior muscle cytosolic homogenates is expressed as mean fold change  SEM from age-matched WT
at 65 days of age *P = 0.016 (WT n = 6, SOD1G86R n = 7) and 105 days of age ***P < 0.0001 (n = 5/genotype), two-way ANOVA followed by Fisher’s LSD post hoc test.
Data shown are representative of two independent experiments having similar results.
B Pyruvate was measured in whole tibialis anterior muscle tissue homogenates. The mean fold change  SEM compared to age-matched WT are represented with
*P = 0.019 at 65 days of age (n = 5/genotype) and *P = 0.041 at 105 days of age (n = 4/genotype), two-way ANOVA followed by Fisher’s LSD post hoc test. Data
shown are representative of two independent experiments having similar results.
C Left: Representative Western blot showing glycogen synthase and phosphorylated glycogen synthase levels. Right: Quantification represents the mean ratio of optical
densities of glycogen synthase/P-glycogen synthase  SEM. At 65 days of age n = 6/genotype, *P = 0.0162, and at 105 days of age n = 5/genotype, *P = 0.0163, two-
way ANOVA followed by Fisher’s LSD post hoc test.
D Left: Representative microphotographs of PAS staining from WT and SOD1G86R tibialis anterior cross-sections at 65 and 105 days of age showing glycogen-negative
(light pink) and glycogen-positive (dark pink) fibers. Scale bar: 200 lm. Right: Quantification of glycogen-negative () and glycogen-positive (+) fibers at 65 and
105 days of age. For () fibers: **P-values versus WT: 0.0026 at 65 days and 0.0074 at 105 days, for (+) fibers: ##P-values versus WT: 0.0025 at 65 days and 0.0073 at
105 days (n = 5/genotype at 65 days and n = 4/genotype at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test).
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BC
A
Figure 4. Altered fuel preference in glycolytic muscle of 65-day-old asymptomatic SOD1G86R mice.
A Relative mRNA levels of Pdk4 and Pdk2 evaluated by qPCR at the indicated ages in tibialis anterior of WT and SOD1G86R mice. Graphs represent mean fold change 
from age-matched WT. Pdk4: **P-values versus WT: 0.014 at 65 days and 0.018 at 105 days; Pdk2: ***P-value versus WT < 0.0001 at 105 days. n = 7 and 8 for WT
and SOD1G86R, respectively, at 65 days; n = 5/genotype at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test.
B Relative mRNA levels of genes involved in lipid handling evaluated by qPCR at the indicated ages in tibialis anterior of WT and SOD1G86R mice. Graphs represent mean
fold change  SEM from age-matched WT. P-values versus WT: Lpl **P = 0.0009, Cd36 *P = 0.051, Acsf2 ***P < 0.0001 at 65 days, **P = 0.0059 at 105 days and
Cpt-1b **P = 0.01 at 65 days and *P = 0.02 at 105 days (n = 6 and 7 for WT and SOD1G86R, respectively, at 65 days; n = 10 and 8 for WT and SOD1G86R, respectively,
at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test).
C Relative levels of (left) ATP and (right) NADH and NAD+ measured in total tibialis anterior homogenates of WT and SOD1G86R mice. Left: Graphs represent mean fold
change  SEM in ATP from age-matched WT. **P = 0.002 (n = 9 and 12 for WT and SOD1G86R, respectively, at 65 days; n = 10/genotype at 105 days, two-way
ANOVA followed by Fisher’s LSD post hoc test). Right: The amounts of NADH and NAD+ relative to protein content in whole tibialis anterior homogenates are
represented as mean  SEM. *P = 0.027 and **P = 0.001 (n = 5, Student’s t-test).
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NMJ destabilization and denervation could underlie Pdk4 induction
in TA muscle observed in SOD1G86R mice.
Pdk4 up-regulation is associated with an increase of the lipid
handling pathway
Hence, we sought to better understand the metabolic significance
of Pdk4 up-regulation through RT–qPCR analyses of genes
involved in lipid handling. When compared to WT littermates,
65-day-old SOD1G86R mice had a significant increase in the expres-
sion of genes encoding lipoprotein lipase (Lpl, 81.2%), Cd36
(18.7%), acylCoA synthetase (Acsf2, 50%), and carnitine palmitoyl
transferase 1B (Cpt-1b, 70%) (Fig 4B). At the end stage of disease,
the expression of Lpl and Cd36 in SOD1G86R mice was comparable
to that of WT littermates, while Acsf2 was decreased by 40% and
Cpt-1b was increased by 45% (Fig 4B). In SOD1G93A mice (Supple-
mentary Fig S2E and F), Cpt-1b and Lpl were decreased at the
onset stage of disease and stayed below control levels until disease
end stage. Only at this latter stage were Pparb/d and Foxo1 mRNA
levels significantly repressed or increased (Supplementary Fig S2G
and H).
Increased expression of genes encoding an enzyme that hydro-
lyses triglycerides to facilitate the uptake of free fatty acids (LPL)
(Mead et al, 2002), a membrane translocase that promotes FA
entry into the cell (CD36), an enzyme that catalyses the conversion
of FA to AcylCoA (ACSF2), and the rate-limiting enzyme for
b-oxidation responsible for the FA transfer into the mitochondria
(CPT-1B) (McGarry et al, 1983) in asymptomatic SOD1G86R mice
suggests that fatty acids intake is increased into glycolytic muscle
tissue when ALS occurs. Taken together with the increased
expression of Pdk4, our data indicate that higher levels of
b-oxidation exist in glycolytic muscle prior to denervation. Given
that adenosine triphosphate (ATP) and reduced nicotinamide
adenine dinucleotide (NADH) are two energetic substrates
produced by b-oxidation and oxidative phosphorylation in the
mitochondria that are known to stimulate PDK activity (for review,
see Harris et al, 2002), we measured the variation in these mole-
cules in the TA of SOD1G86R mice and WT littermates at 65 and
105 days of age. We evidenced a significant increase in ATP and
NADH levels (1.37- and 1.49-fold change, respectively) in 65-day-
old SOD1G86R mice compared to WT while NAD+ levels were
comparable (Fig 4C). Interestingly, ATP and NADH levels were
similar between SOD1G86R mice and WT littermates at 105 days of
age while NAD+ levels were increased 2.6-fold. Finally, mRNA
levels of Pparb/d and Foxo1 were increased in 65-day-old SOD1G86R
mice (Fig 5A and B). Further, mRNA levels of citrate synthase, the
first enzyme of the Krebs cycle, were comparable to WT at 65 days
of age but significantly reduced at end stage (Fig 5C). These data,
together with the inhibition of glycolysis described in the previous
section, clearly demonstrate that an early change in fuel preference
from glucose toward lipids in glycolytic muscle fibers occurs before
denervation in SOD1G86R mice.
The metabolic switch in glycolytic muscle occurs independent
of PGC-1a
The processes that promote the mobilization and use of fatty acids
for ATP synthesis during moderate exercise are subjected to
multiple regulatory steps. Typically, increased oxidative capacity
and lipid use in muscle is accompanied by a switch in muscle fiber
subtype, a phenomenon that is facilitated by peroxisome proliferator-
activated receptor gamma co-activator 1-alpha (PGC-1a), the
master regulator of mitochondrial biogenesis and function (Wu
et al, 1999; Lin et al, 2002). We thus analyzed the expression of
PGC-1a in the TA of SOD1G86R mice. At 65 days of age, Pgc-1a
mRNA and protein levels were similar between SOD1G86R and WT
mice (Fig 5D and E), whereas they were significantly decreased at
105 days of age in SOD1G86R mice. Importantly, at the end stage of
the disease the decrease in PGC-1a protein levels correlated with a
decrease in the mRNA expression of the main target genes of
PGC-1a pathway, estrogen-related receptor a (ERRa), mitofusin
2 (Mfn2), and nuclear respiratory factor 1 (Nrf1) (Puigserver,
2005; Villena & Kralli, 2008) (Fig 5E). ERRa mRNA expression was
reduced by more than 5-fold, Mfn2 mRNA levels were decreased
by 2-fold, and Nrf1 was decreased by 30% in SOD1G86R mice when
compared to WT animals at 105 days (Fig 5F). In addition, mito-
chondrial DNA quantification indicated a decreased number of
mitochondria in TA of SOD1G86R mice toward the end stage of
disease (Fig 6A). Interestingly, this decrease in mitochondrial DNA
was not observed in the soleus muscle. These data suggest that
increased activation of the lipid oxidation pathways in skeletal
muscle of SOD1G86R mice occurs independently of PGC-1a and that
this metabolic change does not have the support of the mitochon-
drial machinery of the cell. Presumably, this would have deleteri-
ous effects due to accumulation of b-oxidation by-products and
ROS (Bonnard et al, 2008). Indeed, glutathione peroxidase 1 (GPX1),
an important indicator of oxidative stress, was increased in the TA
but not the soleus of SOD1G86R mice at end stage of disease
(Fig 6B).
Restoring metabolic equilibrium facilitates weight gain and delays
the onset of motor symptoms and denervation in SOD1G86R mice
In order to ascertain whether decreased glycolytic capacity
in SOD1G86R mice significantly impacts weight loss (due to the
mobilization of fat) and muscle function and pathology that is
commonly observed in ALS (Dupuis et al, 2011), mice were
treated with dichloroacetate (DCA), a halogenated organic acid
that inhibits the activity of PDK and facilitates the entry of
pyruvate into the Krebs cycle and the oxidation of glucose. By
inhibiting PDK and preventing PDH phosphorylation, we aimed to
force metabolism toward glucose oxidation (Abdel-Aleem, 1996),
thereby reversing the metabolic alterations observed in SOD1G86R
mice, preventing weight loss, reducing the toxic effects of lipids
on mitochondria, and delaying denervation in glycolytic muscle
fibers. We administered DCA daily in drinking water from 60 to
95 days of age. At the beginning of treatment (T0), SOD1
G86R mice
in both treated (DCA) and non-treated (CT) groups were signifi-
cantly leaner that WT mice (Supplementary Fig S7A). Over five
weeks of treatment, SOD1G86R mice that received drinking water
(CT) maintained their initial weight. By contrast, SOD1G86R mice
receiving DCA increased their initial weight by 10.8%, an increase
that was similar to that observed in CT WT mice over the same
treatment period (Supplementary Fig S7A and B). DCA had no
effect on the weight gain of WT animals (Supplementary Fig S7A
and B).
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Daily administration of DCA was able to reverse the changes in
Pdk4, Pparb/d, and Foxo1 mRNA expression in SOD1G86R mice
(DCA) when compared to non-DCA-treated SOD1G86R mice (CT,
Fig 7A–C). At the cessation of treatment, Pfk1, Acsf2, and citrate
synthasemRNA levels in DCA-treated SOD1G86R mice were compara-
ble to DCA-treated WT mice (Fig 7D–F), indicating successful resto-
ration of glycolysis and activation of the Krebs cycle. Importantly,
CT SOD1G86R mice presented with significantly reduced Pfk1 and
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Figure 5. Transcription factors, PGC-1a, and citrate synthase are differentially regulated in SOD1G86R mice.
A–D Relative mRNA levels of (A) Pparß/d, (B) Foxo1, (C) citrate synthase, and (D) Pgc-1a were evaluated by qPCR at the indicated ages in tibialis anterior of WT and
SOD1G86R mice. Graphs represent mean fold change  SEM from age-matched WT. P-values versus WT: Pparb/d **P = 0.0016 at 65 days; Foxo1 ***P = 0.0001 at
105 days, citrate synthase ***P < 0.0001 at 105 days, Pgc-1a *P = 0.0104 at 105 days (n = 7 and 8 for WT and SOD1G86R, respectively, at 65 days; n = 5/genotype
at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test).
E Representative Western blot of PGC-1a and respective actin that was used for normalization. PGC-1a protein levels in tibialis anterior muscle tissue are
represented as mean fold change  SEM from age-matched WT. **P-values versus WT: 0.02 (n = 6/genotype at 65 days; n = 5/genotype at 105 days, two-way
ANOVA followed by Fisher’s LSD post hoc test).
F Relative mRNA levels of ERRa, Mfn2, and Nrf1 were evaluated by qPCR at the indicated ages in tibialis anterior of WT and SOD1G86R mice. Graphs represent mean
fold change  SEM from age-matched WT. P-values versus WT: ERRa ***P < 0.0001, Mfn2 **P = 0.002 and Nrf1 **P = 0.009 (n = 6–7 and 7–8 for WT and
SOD1G86R, respectively, at 65 days; n = 5 and 6 for WT and SOD1G86R, respectively, at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test).
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citrate synthase expression when compared to DCA-treated
SOD1G86R mice and/or CT WT mice. DCA treatment was also able to
preserve the expression of Pgc-1a and its target gene Mfn2 in DCA-
treated SOD1G86R mice at levels comparable to that seen in CT WT
and DCA-treated WT mice (Fig 7G and H). The increase in the
expression of genes involved in mitochondrial biogenesis was
accompanied by a decrease in the expression of the Gpx1 (Fig 7I).
Notably, and in support of our results above, 95-day-old CT
SOD1G86R mice presented with a significant decrease in the expres-
sion of Pgc-1a and Mfn2 mRNA and an increase in the expression of
Gpx1 mRNA (Fig 7G–I). Collectively, these data suggest that DCA is
able to restore glycolytic function while decreasing oxidative stress
in glycolytic muscle of SOD1G86R mice.
At a functional level, DCA was able to almost completely
preserve muscle strength. While CT SOD1G86R mice lost 30% of their
grip strength, DCA-treated SOD1G86R mice only lost 8% of their grip
strength when compared to initial grip force at the initiation of treat-
ment (Fig 8A). This increased grip strength was associated with an
increase in both oxidative and glycolytic muscle fiber size in TA
(Supplementary Fig S7D and E). Analysis of mRNA expression of
muscle atrophy markers showed a more modest improvement
(Fig 8B). Murf-1 mRNA expression was reduced from a 1.6-fold
increase in the non-treated CT SOD1G86R mice to 1.3-fold increase in
DCA-treated SOD1G86R mice. Similarly, Atg-1 mRNA expression was
decreased from a 1.7-fold increase in CT SOD1G86R mice to a 1.4-fold
increase in DCA-treated SOD1G86R mice. DCA treatment also
prevented the increase in the expression of the denervation markers
(Fig 8C). The increase in expression of AChRa mRNA in DCA-treated
SOD1G86R mice was only 3.2-fold as compared to an 8.8-fold increase
in CT SOD1G86R mice. AChRc mRNA was increased by 3.9-fold in
DCA-treated SOD1G86R mice as compared to a 15.87-fold increase
measured in CT SOD1G86R mice. Lastly, MuSK gene expression was
A
B
Figure 6. Altered mitochondrial function in glycolytic muscle of SOD1G86R mice.
A Mitochondrial DNA (mtDNA) was quantified using qPCR. Relative mtDNA levels are expressed as the ratio between mitochondrial-encoded gene Cox1 and the
nuclear-encoded gene cyclophilin A. Graphs represent mean fold change  SEM from age-matched WT for tibialis anterior (left panel) and soleus (right panel) of WT
and SOD1G86R mice. ***P < 0.0001 (n = 5 and 4 for WT and SOD1G86R, respectively, at 65 days; n = 6/genotype at 105 days, two-way ANOVA followed by Fisher’s LSD
post hoc test).
B Relative mRNA levels of Gpx1 were measured by qPCR at the indicated ages in tibialis anterior (left panel) and soleus (right panel) of WT and SOD1G86R mice. Graphs
represent mean fold change  SEM from age-matched WT. ***P < 0.0001 (n = 7 and 8 for WT and SOD1G86R, respectively, at 65 days; n = 9 and 8 for WT and
SOD1G86R, respectively, at 105 days, two-way ANOVA followed by Fisher’s LSD post hoc test).
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also lower following treatment with DCA, decreasing from a 2-fold
increase in CT SOD1G86R mice to a 1.3-fold increase in DCA-treated
SOD1G86R mice. WT mice treated with DCA did not present with any
modifications of these atrophy or denervation markers. Altogether,
these results demonstrate that by facilitating the equilibrium
between glucose and lipid oxidation through the administration of
DCA, we are able to promote weight gain, restore mitochondrial
gene expression, improve muscle strength, and decrease the expres-
sion of denervation markers in SOD1G86R mice.
Discussion
Here, we provide evidence of a change in the metabolic capacity
of glycolytic muscle in SOD1G86R mice. A switch from glucose
metabolism to lipid metabolism occurs early in the disease process
and prior to any detectable motor and clinical (EMG alteration)
symptoms. By improving glycolytic capacity in SOD1G86R mice
through administration of DCA, we promoted a delay in the onset of
motor symptoms and amelioration of muscle denervation and
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Figure 7. DCA treatment had beneficial effects on metabolism and mitochondrial function of SOD1G86R mice.
A–I Relative mRNA levels of (A) Pdk4, (B) Pparb/d, (C) Foxo1, (D) Pfk1, (E) Acsf2, (F) citrate synthase, (G) PGC-1a, (H) Mfn2, and (I) Gpx1 were evaluated by qPCR in tibialis
anterior of control (CT) or DCA-treated (DCA) WT and SOD1G86R mice. Graphs represent mean fold change  SEM from CT WT group. P-values versus WT: Pdk4
***P = 0.002 and ##P = 0.0039, Pparb/d #P = 0.0178, Foxo1 **P = 0.0033 and ##P = 0.0038, Pfk1 ***P = 0.0002 and ##P = 0.0080, Acsf2 *P = 0.0437, citrate
synthase ###P = 0.0004, Pgc-1a **P = 0.0084 and ###P = 0.0009, Mfn2 *P = 0.0272, $P = 0.0145 and ###P = 0.0002 and Gpx1 ***P < 0.0001 and ###P < 0.0001
(n = 9/genotype in CT groups, n = 9 and 8 for WT and SOD1G86R, respectively, in DCA group, two-way ANOVA followed by Fisher’s LSD post hoc test).
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atrophy. Thus, we demonstrate for the first time that an early switch
to lipid metabolism in skeletal muscle may underlie early pathologi-
cal mechanisms associated with NMJ destabilization in ALS.
The decreased capacity for SOD1G86R mice to endure acute
physical exercise that solicits anaerobic metabolism in muscle
occurred before any measurable muscle weakness or overt dener-
vation (Figs 1 and 2). This low resistance to intense exercise
contrasted their enhanced endurance capacity during acute aerobic
exercise. This observation suggests that SOD1G86R mice acquire
new properties in skeletal muscle that enhance global aerobic
capacity and promote endurance ability. It is plausible that altered
glucose and insulin responses in SOD1G86R mice (Supplementary
Fig S1) might underlie this change in exercise capacity since insu-
lin plays a critical role in driving glucose uptake into skeletal
muscle for use as an energy substrate. Indeed, high incidences of
glucose intolerance have been observed in patients diagnosed with
sporadic ALS (Pradat et al, 2010). However, as basal glucose
uptake in extensor digitorum longus (EDL: another glycolytic
muscle) of the SOD1G93A mouse model of ALS is normal before
overt denervation (Smittkamp et al, 2014), it would seem unlikely
that altered insulin sensitivity underlies the metabolic changes
observed in this study.
Endurance exercise is also supported by slow-twitch oxidative
type I fibers while intense exercise requires movements involving
strength and speed that are generated by fast-twitch glycolytic type
IIb fibers (Bassel-Duby & Olson, 2006). Given that a switch in fiber
type from glycolytic to oxidative fibers has been described in ALS
patient muscle biopsies (Telerman-Toppet & Coe¨rs, 1978), and in
the SOD1G93A mouse model of ALS (Atkin et al, 2005; Hegedus et al,
2008; Deforges et al, 2009), the observed alteration in exercise
capacity in SOD1G86R mice might also reflect a switch of muscle
fiber type. In line with this, enhanced aerobic capacity is typically
observed after endurance training, and this occurs concurrent with
measurable changes in fiber type composition (Pette & Staron,
2001).
PFK1 is the rate-limiting enzyme of the glycolysis, and an
increase in glycogen synthase activity and glycogen accumulation
in skeletal muscle is characteristic of a muscle that is subjected to
endurance training (Vestergaard, 1999). Thus, the increase in
endurance capacity in SOD1G86R mice mirrors a profound alteration
A B
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Figure 8. DCA treatment had protective effects on muscle strength and prevented the expression denervation markers.
A Grip strength is represented as mean of percent from T0 for each experimental group  SEM. ##P = 0.0045 and ***P = 0.0003 (n = 9/genotype in CT groups, n = 9
and 8 for WT and SOD1G86R, respectively, in DCA group, two-way ANOVA followed by Fisher’s LSD post hoc test).
B Relative mRNA levels of muscular atrophy markers Murf1 and Atg-1 were measured by qPCR in tibialis anterior of control (CT) or DCA-treated (DCA) WT and SOD1G86R
mice. Graphs represent mean fold change  SEM from CT WT group. **P = 0.0079 and ***P = 0.0018 (n = 9/genotype in CT groups, n = 9 and 8 for WT and
SOD1G86R, respectively, in DCA group, two-way ANOVA followed by Fisher’s LSD post hoc test).
C Relative mRNA levels of denervation markers AChRa, AChRc, and MuSK were measured by qPCR in tibialis anterior of control (CT) or DCA-treated (DCA) WT and SOD1G86R
mice. Graphs represent mean fold change  SEM from CT WT group. **P = 0.015 for AChRa, #P = 0.028 and **P = 0.074 for AChRc, #P = 0.042 and **P = 0.0029 for
MuSK (n = 9/genotype in CT groups, n = 9 and 8 for WT and SOD1G86R, respectively, in DCA group, two-way ANOVA followed by Fisher’s LSD post hoc test).
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of fuel preference in muscle fibers. In accordance with this, we
observed a progressive decrease of PFK1 activity, and an increase
in glycogen synthase activity and glycogen accumulation in skele-
tal muscle. The initial decrease in PFK1 activity in SOD1G86R mice
may be an adaptive response to the progressive accumulation of
pyruvate and increased FA uptake, two well-known potent inhibi-
tors of PFK1 (Massao Hirabara et al, 2003). Furthermore, as the
entry of glucose into muscle fibers in ALS mice is not affected
early in disease (Dupuis et al, 2004; Smittkamp et al, 2014), our
data suggest that glucose is rerouted toward glycogen stores rather
than being used as an immediate energy source. By the end stage
of disease, reduced activities of PFK1 and glycogen synthase,
together with an increase of glycogen stores and reduced levels of
pyruvate, demonstrate inhibition of the glycolytic pathway. Collec-
tively, these observations suggest that glycolytic muscle is no
longer able to mobilize glycogen stores to produce energy and that
the inhibition of glycolysis appears to originate downstream of
PFK1 (Fig 9).
In contrast to inhibition of glycolysis in SOD1G86R mice, the
lipid pathway was stimulated at 65 days of age and remained
functional until the end stage of disease (Fig 4B and C). It is
known that increased endurance should correlate with increased
release of fatty acids from lipid stores, and enhanced uptake by
muscle tissue (Talanian et al, 2010). Previous observations of
decreased fat pad mass and respiratory quotient at an early stage
in SOD1G86R mice (Dupuis et al, 2004) and increased lipid clear-
ance in these mice (Fergani et al, 2007) are indicative of increased
lipid use. Moreover, in patients diagnosed with sporadic ALS,
Pradat and colleagues reported increased circulating free fatty acids
(FFAs) (Pradat et al, 2010). Altogether, these observations indicate
that muscle tissue of SOD1G86R is the potential site of abnormal
lipid consumption. The question raised from these observations
was whether the more ‘efficient’ oxidation during exercise is due
to a given group of muscles that work more efficiently or whether
other groups of muscles are becoming oxidative to participate in
the exercise task. The latter appears to occur since fiber type
A B
Figure 9. Schematic representation of the described metabolic imbalance in glycolytic muscle fibers of SOD1G86R mice.
A Under normal conditions in WT mice, both glucose and lipids enter the cell and are used as cellular fuels. In this situation, both pathways are used and are driven by
PDK4 according to needs and fuel availability.
B In the case of ALS, metabolic flexibility is lost because of chronically increased PDK4 and subsequent inhibition of PDH and PFK1 leading to glycogen accumulation.
Increased lipid use through b-oxidation that can only function under aerobic conditions may underlie the greater endurance capacity in SOD1G86R mice. With time,
the cell produces more reactive oxygen species, thereby inducing cellular damage.
Data information: CD36, CD36 antigen/fatty acid translocase, CPT1, carnitine palmitoyl transferase 1, FAs, fatty acids, FA-CoA, acyl-fatty acids, GLUT4, glucose transporter 4,
LPL, lipoprotein lipase, PDH, pyruvate dehydrogenase complex, PDK4, pyruvate dehydrogenase kinase 4, PFK1, phosphofructokinase 1, ROS, reactive oxygen species.
Drawing was performed with the website Somersault1824 (http://www.somersault1824.com).
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switching toward more oxidative metabolism (Deforges et al,
2009), and increased expression of genes encoding enzymes
involved in lipid metabolism (Dupuis et al, 2004; Fergani et al,
2007) is observed at later, symptomatic stages of disease in ALS
mouse models. In line with this, we show an early increase in the
gene expression of important components in lipid mobilization and
uptake (Lpl, Cd36, ACSF2, and Cpt-1B, Fig 4B), and increased
b-oxidation by-products (ATP and NADH at 65 days) that activate
PDK4 and inhibit PDH activity (Denton et al, 1975) in fast-twitch
glycolytic muscle.
PDK4 appears to play a pivotal role in the switch in fuel prefer-
ence by orchestrating substrate competition in SOD1G86R glycolytic
muscle fibers. In skeletal muscle, PDK4 is the most highly expressed
pyruvate dehydrogenase kinase isoform and is considered to be a
critical regulator of pyruvate dehydrogenase (PDH) activity
(Bowker-Kinley et al, 1998). In this study, we show that Pdk4
expression is induced not only in two mutant SOD1 mouse models
but also in sporadic ALS patients (Fig 4, Supplementary Figs S2 and
S4). These data show that the induction of Pdk4 expression is not
specific to SOD1 mutations but is rather an ALS-specific phenome-
non. By phosphorylating PDH, PDK4 completely inhibits the entry
of pyruvate into the Krebs cycle, thus hampering glucose oxidation
(for review, see Holness & Sugden, 2003). PDH and PDK4 are
known to act as metabolic homeostat in response to energy imbal-
ance. Indeed, PDK4 transcription is increased during prolonged
exercise, after both short-term high-intensity and prolonged low-
intensity exercise or during fasting, situations that represent meta-
bolic states where the whole body glucose availability is in deficit
(Spriet et al, 2004; Watt et al, 2004; Jeong et al, 2012). Pdk4 expres-
sion is controlled directly or indirectly by various transcription
factors/transcriptional coactivators or stimuli, including PPARb/d,
FOXO1, PGC-1a, ERRa, or FAs. In C2C12 mouse myoblasts, nutrient
deprivation induces Pdk4 gene expression (Furuyama et al, 2003).
In rat muscle tissue, triglyceride infusion leads to increased plasma
FA and increased expression of Pdk4 mRNA (Kim et al, 2006).
Moreover, it has been shown that in response to increased entry of
FA in skeletal muscle or to fasting, induction of PPARb/d stimulates
FOXO1 transcription, which in turn activates Pdk4 expression
(Nahle´ et al, 2008). Here, we show that Pdk4 activation might occur
in response to the increase in Pparb/d and Foxo1 mRNAs, rather
than via the classical transcription factors PGC-1a/ERRa. If this
were the case, then an increase of FA release due to the induction of
Lpl and Acsf2 would stimulate PDK4 expression via PPARb/d and
FOXO1, which would in turn facilitate FA oxidation by conserving
pyruvate for oxaloacetate formation to allow entry of acetyl-coA into
the Krebs cycle (Fig 9). In SOD1G93A mice, although induction of
Pdk4 expression is detected at the onset (63–75 days old), the global
metabolic profile of the mice differs from the one found in SOD1G86R
mice. It is highly likely that the observed differences are a result of
profound mitochondrial alterations which have been described in
the SOD1G93A mice as early as post-natal day 30 (for review, see
Vinsant et al, 2013a,b).
The question of the role of NMJ destabilization in the metabolic
switch clearly remains open. We showed here that synaptic alter-
ation/dysfunction obtained 24 h after sciatic nerve crush is sufficient
to induce an early but transient increase in Pdk4 mRNA, which then
returns to initial levels despite a sustained increase in the levels of
AChRa mRNA, an accepted marker of NMJ denervation. In the
SOD1G86R, Pdk4 mRNA is induced before any detectable sign of
denervation by EMG and before the increased expression of the
denervation makers used in this study. However, we cannot
exclude a lack of sensitivity of our techniques. In the SOD1G93A
mice, denervation events have been detected at 30 days of age
through a detailed study of the NMJ by electron microscopy
(Vinsant et al, 2013a,b), and impaired neuromuscular transmis-
sion has been detected at 28–42 days of age (Rocha et al, 2013),
long before the onset of motor symptoms. Here, we showed that,
at the same period, Pdk4 mRNA levels are comparable to those
found in WT mice. Altogether, these data show that NMJ dysfunc-
tion or destabilization might participate to the Pdk4 mRNA induc-
tion.
Another interesting aspect of the mechanism described here is
the consequence of prolonged use of lipids as an energy substrate.
Increased b-oxidation of fatty acids leads to the generation of lipid
by-products that contribute to lipotoxicity and ROS production
(Zhang et al, 2010; Aon et al, 2014). ROS accumulation in muscle
tissue of SOD1G86R mice is an early event in the course of the patho-
logy that precedes overt signs of denervation (Halter et al, 2010).
Here, we show an up-regulation of Gpx1, an indicator of ROS accu-
mulation, in the TA but not in the soleus muscle of SODG86R mice in
the advanced stages of the disease. It is expected that this chronic/
long-term activation of lipid use would have toxic effects on mito-
chondria (Bonnard et al, 2008), which might explain the observed
decrease of citrate synthase (Fig 5C), the decrease in the expression
of genes responsible for mitochondrial dynamics, and the reduction
in the quantity of mtDNA specific to glycolytic muscle (Fig 6).
Indeed, rescuing muscle mitochondria in a mouse model for ALS
through the overexpression of muscle-specific PGC-1a has been
shown to prevent muscle atrophy and improve mitochondrial func-
tion (Da Cruz et al, 2012). Although PGC-1a is often considered as
the main ‘fiber type regulator’ that contributes to muscle physiologi-
cal plasticity under normal physiological conditions, PGC-1a is
down-regulated with disease progression in our SOD1G86R mice and
can therefore not account for the induction of Pdk4. Alternatively,
muscle-specific over-expression of PPARb/d in skeletal muscle
results in a greater number of oxidative type 1 fibers (Luquet et al,
2003), and over-expression of constitutively active PPARb/d results
in mitochondrial biogenesis and a shift from fast-twitch to slow-
twitch fibers (Wang et al, 2004). Thus, the early switch of fuel
preference in ALS mice could be driven by the increased expression
of PPARb/d. Altogether, these findings show that metabolic imbal-
ance in muscle fibers of SOD1G86R mice is an early event. As glyco-
lytic muscle fibers become progressively unable to use glucose as an
energy substrate, they switch to lipid use to maintain a sufficient
amount of energy supply. Intriguingly, this mechanism is specific to
glycolytic muscle fibers as the deregulations observed in the TA
differ from that seen in the oxidative soleus muscle.
Because PDK4 appears to be a key player in the switch in fuel
preference by suppressing glucose utilization, we used the halo-
genated carboxylic acid DCA, a specific inhibitor of PDK, to restore
glucose metabolism and muscle metabolic plasticity. Indeed, main-
taining PDH in its unphosphorylated active form will re-activate
PDH function and recover glucose metabolism by restoring glucose
oxidation (Whitehouse & Randle, 1973). In a model of statin-
induced muscle atrophy, DCA treatment has been shown to increase
glucose oxidation in type IIb muscle fibers and reduce the
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expression of markers of protein degradation (Mallinson et al,
2012). This is in line with the results presented here. In this study,
we demonstrate that DCA treatment exerts protective effects on
muscle fibers in the SOD1G86R mice by restoring the ability of glyco-
lytic muscle to use glucose as fuel. When compared to non-DCA-
treated SOD1G86R mice, those supplemented with DCA show a
decrease in the mRNA expression of Pdk4, Foxo1, and Pparb/d in
parallel with an induction of Pfk1 and citrate synthase. Moreover,
DCA-treated SOD1G86R mice also had decreased expression of dener-
vation and atrophy markers when compared to untreated SOD1G86R
mice. At a functional level, this was reflected by a preservation of
muscle strength and the presence of larger muscle fibers in DCA-
treated SOD1G86R mice compared to untreated SOD1G86R mice. DCA
treatment in SOD1G86R mice also exerted beneficial metabolic effects
in the whole organism by stimulating weight gain during disease
development, which is similar to what has been observed after DCA
treatment of statin-induced myopathy in mice (Mallinson et al,
2012). It is important to note that DCA treatment was able to restore
some of the biochemical parameters that govern fuel use in
SOD1G86R mice (Fig 7). We observed an up-regulation of mRNA
expression of Pgc-1a and Mfn2, a PGC-1a target gene that is involved
in mitochondrial dynamics. While DCA has not been shown to
directly regulate the PGC-1a pathway, it has been shown to reverse
the inhibition of PGC-1a and mitochondrial biogenesis that is
induced in myotubes by chronic inhibition of glucose oxidation with
pyruvate (Philp et al, 2010). The beneficial effects on mitochondrial
metabolism following DCA treatment in SOD1G86R mice were also
reflected by comparable levels of Gpx1 in DCA-treated SOD1G86R
mice and CT- and DCA-treated WT mice. Collectively, these data
show that restoration of metabolic equilibrium in glycolytic muscle
fibers is able to protect muscle mitochondria and prevent oxidative
stress, while also preventing denervation and atrophy.
DCA has previously been used in the SOD1G93A mouse model of
ALS (Miquel et al, 2012). By limiting pyruvate turnover to lactate
and facilitating the entry of pyruvate into the Krebs cycle, DCA
reduced astrogliosis and motor neuron death (Miquel et al, 2012).
This indicates that PDK activation may be a common mechanism in
astrocytes and muscle. Interestingly, Miquel and colleagues also
demonstrated that DCA-treated SOD1G93A mice presented with a
marked improvement in the structure of NMJs in the extensor digito-
rum longus (glycolytic muscle fiber) but not soleus (oxidative
muscle fiber). Taken together with our data showing an effect of
DCA in restoring glycolysis in muscle, one can conclude that DCA
treatment exerts its protective effects through stabilizing the NMJ.
However, based on the action of DCA on both muscle and astro-
cytes, we cannot conclude whether the normalization of glycolytic
muscle metabolism is sufficient in itself to maintain the positive
effect observed at the NMJ. However, our data provide convincing
evidence that DCA treatment promotes the use of glucose as the
preferred energy substrate (instead of lipids), thereby preventing
denervation and maintaining function at NMJ.
In conclusion, our study provides compelling evidence to support
a dramatic change in glycolytic muscle metabolism that specifically
alters muscle metabolic plasticity in highly susceptible glycolytic
fibers. Importantly, these metabolic alterations occur very early in
the course of the disease. These data, in combination with our
sciatic nerve crush and axotomy experiments, suggest that glycolytic
defects might be due to additional events distinct from denervation.
However, early changes of synaptic functionality might contribute
to early stages of the metabolic switch, which in turn could contrib-
ute to further NMJ changes and a self-propagating process. Impor-
tantly, since altered metabolic plasticity might underlie the
susceptibility of glycolytic fibers to denervation while limiting the
capacity for muscle to become re-innervated, this would have detri-
mental effects on the rate of disease progression. By demonstrating
the involvement of multiple cell types in ALS pathology and identi-
fying a possible common metabolic thread between glycolytic
muscle and astroglia in ALS pathogenesis, our work further exem-
plifies the complexity of ALS. Finally, our work has important thera-
peutic implications as we present evidence to suggest that by
improving metabolic function in murine ALS animal model through
DCA, it is possible to improve motor function, maintain muscular
integrity, and delay denervation.
Materials and Methods
Ethics statement
All experiments performed with mice followed current European
Union (Directive 2010/63/EU) and Australian regulations. They
were approved by the regional ethics committee CREMEAS 35 under
number AL/01/20/09/12 and by The University of Queensland
Animal Ethics Committee (ethics number SBMS/562/12/MNDRIA).
They were performed in accordance with national guidelines and in
strict compliance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health (USA) by authorized investigators.
For human biopsies, the study was approved and performed
under the ethical guidelines issued by our institution (University
Hospital of Strasbourg) for clinical studies. The diagnostic proce-
dures were conducted according to the Strasbourg University Hospi-
tal Ethical Committee, and informed written consent was obtained
from all patients.
Muscle biopsy collection
We studied biopsies from the left deltoid muscle of eleven patients
with sporadic ALS. According to the El Escorial criteria, all
patients had definite ALS. The control group included seven
patients subjected to a standard surgical diagnosis procedure with-
out significant neurological history. All patients gave written
informed consent before biopsy. Tissues were immediately frozen in
liquid nitrogen and stored at 80°C until use.
Animals
FVB/N males overexpressing murine SOD1 with the G86R mutation
or C57/Bl6 males overexpressing human SOD1 with the G93A
mutation [B6.Cg-Tg(SOD1-G93A)1Gur/J] were genotyped as
described previously (Gurney et al, 1994; Ripps et al, 1995). Wild-
type littermates were used as controls. SOD1G93A mice were studied
at predefined stages of disease progression (Ngo et al, 2012). Male
Thy1-YFP mice on FVB background (Feng et al, 2000) were used
for direct identification of presynaptic terminals after nerve crush.
Mice were group-housed (2–5 per cage) in a temperature- and
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humidity-controlled environment at 23°C and under a 12-h light/
dark cycle. Mice had access to water and regular A04 chow ad libi-
tum. Mice with a body weight outside of the standard at the time
of the selection were excluded from the experiments. Blinded inves-
tigators were employed to minimize the effect of subjective bias
when assessing results.
Exercise paradigms
The week before starting the experiment, all animals were accli-
mated to the treadmill exercise (Treadmill Control, Letica, Spain) by
running at 25 cm/s with a 5° inclination for 5 min for 3 days. Mice
were tested at 65–66 days of age.
Intense anaerobic exercise
A maximal incremental test was carried out. The incline was set at
+ 10° and the speed at 40 cm/s and was maintained at this rate for
2 min. The speed was then increased by 3 cm/s every 90 s until
exhaustion of the animal. The speed at which each mouse stopped
running was considered to be the maximal running speed (Vmax).
Low-intensity endurance exercise
To determine maximal endurance capacity, a rectangular test was
established. All mice ran at 80% of the Vmax attempt during the
maximal incremental test. The incline was set at + 10°, and after
2 min of acclimation at 40 cm/s, the speed was maintained at 80%
of the Vmax until exhaustion.
The criterion for exhaustion was a time of 5 s spent on the electri-
cal grid without running. Blood samples from the tip of the tail were
obtained immediately at the end of exercise to measure blood lactate
using a lactate pro-LT device (Lactate Pro LT-1710, Arkray, China).
Muscle grip strength
Muscle grip strength was measured using a strength meter (Bioseb
Grip test, Bioseb, France). Animals were placed over a metallic
grid that they instinctively grab to stop the involuntary backward
movement carried out by the manipulator until the pulling force
overcomes their grip strength. Each animal was pulled over the
entire length of the metallic grid until it lost its grip. Grip strength,
expressed in Newton, was recorded over three trials for each animal
in each test session. The maximal grip strength was obtained by
averaging the three grip strength scores for each animal. All record-
ings were performed by the same blinded investigator to minimize
variability in the experimental procedure.
Electromyography
All recordings were performed with a standard EMG apparatus
(Dantec, Les Ulis, France) in accordance with the guidelines of the
American Association of Electrodiagnosis Medicine (AAEM). Mice
were anesthetized with 100 mg/kg ketamine chlorhydrate and
5 mg/kg xylazine and maintained at 36°C over a thermostatic blan-
ket. In order to minimize variability, all recordings were performed
by the same blinded investigator. Recordings were monitored for
2 min with a concentric needle electrode (9013S0011, diameter
0.3 mm; Medtronic, USA) inserted into the gastrocnemius muscle. A
monopolar needle electrode (9013R0312, diameter 0.3 mm;
Medtronic) was inserted into the tail of the mouse to ground the
system. Recordings showing voluntary activity were discarded.
Spontaneous activity (mainly fibrillations) characteristic of muscle
denervation was differentiated from voluntary activity (regular
discharges that disappear with muscular relaxation) by visual and
auditory inspection. Spontaneous activity with a peak-to-peak
amplitude of at least 50 lV was considered to be significant.
Glucose tolerance test and insulin tolerance test
65-day-old male transgenic and non-transgenic mice were fasted
for 18 h (starting at 6 PM) prior to the glucose tolerance test
(GTT) or fasted for 4 h (starting at 9 AM) prior to the insulin
tolerance test (ITT). Blood glucose levels were evaluated using a
commercial FreeStyle Papillon InsuLinx glucometer (Abbot,
France). Blood was drawn from a small incision at the tip of the
tail. For GTTs, initial blood glucose was measured prior to an IP
injection of 2 g/kg body mass of glucose. For ITTs, insulin from
bovine pancreas (Sigma-Aldrich, USA) was injected IP (0.5 U/kg
body mass) after initial blood glucose was measured. Changes in
blood glucose were followed for 120 min with measurements
taken every 15 min for both GTTs and ITTs. For each mouse,
blood glucose was expressed as the percentage of initial blood
glucose concentration (T0).
Sciatic nerve crush and axotomy
Axotomy of the sciatic nerve was performed on 8- to 9-week-old
non-transgenic FVB/N male mice. Sciatic nerve crush was performed
on 8- to 9-week-old non-transgenic or Thy1-YFP male mice on a FVB
background. Mice were anesthetized by intraperitoneal injection of
100 mg/kg ketamine chlorhydrate and 5 mg/kg xylazine. The sciatic
nerve was exposed at mid-thigh level and either crushed with a fine
forceps for 30 s (mild nerve crush) or sectioned using microscissors
(axotomy). For the sham animals, skin was opened and the sciatic
nerve was exposed without additional manipulation. The skin inci-
sion was sutured, and mice were allowed to recover. Contralateral
hindlimbs served as control. The efficiency of nerve crush was
confirmed 24 h after injury by gait abnormalities and defects in paw
flexion when the mouse was held by the tail. Mice were sacrificed
by lethal injection of pentobarbital at different time points following
the surgical intervention. Muscles were dissected, snap-frozen for
biochemistry (FVB/N mice), or fixed with 4% buffered paraformal-
dehyde for 30 min for NMJ analysis (Thy1-YFP mice).
NMJ analysis
Fixed muscles from Thy1-YFP mice were cut into bundles. Bundles
were incubated 1 h with tetramethyl rhodamine-conjugated
a-bungarotoxin (aBGT, 1 lg/ml in PBS; Sigma). Fluorescence
staining was monitored with a laser-scanning microscope (confocal
Leica SP5 Leica Microsystems CMS GmbH). Z-stacks of 2-lm optical
sections were analyzed using ImageJ freeware (http://rsbweb.
nih.gov/ij/).
Dichloroacetate treatment
The pharmacological treatment consisted in daily administration
of dichloroacetate (DCA; Sigma-Aldrich) in drinking water at a
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concentration corresponding to a daily dose of 500 mg/kg body
mass as previously described (Miquel et al, 2012). The concentra-
tion was calculated based on a predicted water intake of
5 ml/day/ animal (Bachmanov et al, 2002). For each genotype,
male wild-type and SOD1G86R littermate mice were randomly allo-
cated into experimental groups. Mice with a body weight outside
of the standard at the time of the selection were excluded. Water
intake was carefully monitored throughout the duration of the
experiment. Standard drinking water was used as a control (CT).
Mouse weights were monitored weekly by an investigator who
was blinded to mouse genotypes and treatment groups.
Quantitative RT–PCR
Frozen muscle samples were homogenized in 1 ml/100 mg tissue
TRIzol reagent (Invitrogen, USA) together with a stainless bead.
Two 3-min homogenization cycles were performed in a TissueLyser
(Qiagen, Germany) at 30 Hz. RNA was extracted using chloroform/
isopropyl alcohol/ethanol and stored at 80°C. One microgram of
total RNA was used to synthesize cDNA using Iscript reverse
transcriptase (Bio-Rad, USA) and oligo-dT primer as specified by
the manufacturer. Gene expression was measured using the 2×
SYBR green SsoAdvanced reagent (Bio-Rad) according to the
manufacturer’s instructions on a Bio-Rad iCycler. PCR was
performed under optimized conditions as follows: 95°C denatur-
ation for 30 s, followed by 40 cycles of 10 s at 95°C and 30 s at
60°C. The extended list of primers (Eurogentec, Belgium) is
provided in Supplementary Table S1. Relative expression was
achieved by calculating the ratio between the cycle number (Ct) at
which signal crossed a threshold set within the logarithmic phase
of the gene of interest and that of TBP housekeeping gene. Ct
values were means of duplicates.
Quantification of mitochondrial DNA
Snap-frozen tissue was digested in KTT buffer (Tris 10 mM pH 9,
Triton X-100 0.1%, KCl 50 mM) with 2% proteinase K (Sigma-
Aldrich) overnight at 54°C under constant agitation. Proteinase
K was inactivated at 100°C for 5 min. RNA was degraded with
0.3 lg/ll RNase for 1 h at 37°C. Total DNA was extracted using
a mix of Roti-Phenol reagent (Roth, USA), chloroform, and
isoamyl alcohol (25/24/1). DNA was quantified using RT–qPCR
(initial denaturation step at 98°C for 2 min, followed by 40 cycles of
10 s at 98°C and 20 s at 62°C). The relative mtDNA levels were
calculated by normalizing the relative expression of mitochondrial
Cox1 to the relative expression of the nuclear cyclophilin A. Primer
sequences are provided in Supplementary Table S1.
Western blotting
Snap-frozen muscle tissue was pulverized in a TissueLyser (Qiagen)
for 2 × 20 s under liquid nitrogen using stainless steel beads. Tissue
powder was homogenized in RIPA lysis buffer (50 mM Tris pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5%
sodium deoxycholate) at 1 ml/100 mg tissue containing 1:100 prote-
ase inhibitor cocktail (Calbiochem, USA) and phosphatase inhibitor
cocktails 2 and 3 (Sigma-Aldrich, Germany). Determination of
protein concentration was carried out using a BCA Assay Reagent
Kit (UP95424 Uptima, France). Protein was denaturated by boiling,
resolved by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and transferred to 2-lm nitrocellulose membranes (Bio-Rad,
France) using a semi-dry Transblot Turbo system (Bio-Rad, France).
After using a chemiluminescent blocker (Millipore, France),
membranes were probed with primary antibodies against Glycogen
Synthase Rabbit mAb (Cell Signaling; Cat#3886; 1:500), Phospho-
Glycogen Synthase Ser641 (Cell Signaling; Cat#3891; 1:500), PGC-1a
(Millipore; Cat#AB3242, 1:1,000), and total actin (Sigma-Aldrich;
Cat#A2103, 1:10,000). Primary antibodies were detected with anti-
rabbit HRP (P.A.R.I.S; Cat#BI2407, 1:5,000). The protein bands were
detected by chemiluminescence using ECL Lumina Forte (Millipore)
and a chemiluminescence detector (Bio-Rad, France).
Phosphofructokinase enzymatic activity
For biochemical analysis, mice were sacrificed and tissues were
quickly dissected, frozen in liquid nitrogen, and stored at 80°C
until use. All chemicals were purchased from Sigma-Aldrich. Frozen
tibialis anterior muscles were pulverized with a mortar and pestle
under liquid nitrogen. The powder was resuspended in five volumes
(w/v) of extraction buffer containing 20 mM Tris–HCl pH 7.5,
0.15 M NaCl, and Protease inhibitor cocktail (Calbiochem, USA).
Samples were homogenized by vortexing for 3 min prior to incuba-
tion for 10 min on roller at room temperature. After a final homo-
genization by vortexing for 2 min, samples underwent centrifugation
for 15 min at 10,000 g at 4°C. The supernatant was used for the assay
of PFK activity and determination of protein concentration as
described above.
PFK activity was determined at 25°C in 96-well microplates in a
total volume of 240 ll. An aliquot (10 ll) of tissue extract was
added to 200 ll of reaction cocktail solution (50 mM Tris–HCl pH
8.0, 3 mM MgCl2, 3 mM DTT, 0.1 mM EGTA, 0.3 mM NADH,
2 mM fructose-6-phosphate, 10 IU aldolase, 80 IU triose phosphate
isomerase, 14 IU glycerol-3-phosphodeshydrogenase, and 10 ll of
distilled water). The reaction was started with the addition of 20 ll
of 10-mM ATP. PFK activity was measured every minute over
20 min and calculated from the linear rate of change in absorbance
at 340 nm (Tristar LB 941 apparatus, Berthold Technologies,
Germany). Calculations were based on the extinction coefficient of
6.22 × 103 M for NADH and corrected by the volume of the sample
added, to obtain nmol of NADH oxidized/min/ll of sample. As one
mole of NADH corresponds to one mole of PFK, the activity of PFK
was calculated for each sample relative to the protein concentration
of each sample.
Intermediary metabolites
All intermediary metabolites analyzed were extracted from fresh
snap-frozen tissue. Quantification was performed using commercial
colorimetric assays for pyruvate (K609-100; BioVision, USA), ATP
(K354-100; BioVision), and NAD+ and NADH (ab65348; Abcam,
UK). Samples were deproteinized using 10-kDa cutoff spin filters
(ab93349; Abcam), and assays were performed according to manu-
facturer’s instructions. The optical densities for all assays were
obtained using a Tristar LB 941 multimode plate reader (Berthold
Technologies, France), and raw concentration values were calcu-
lated as indicated by the manufacturer.
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Histochemistry and morphometry
Glycogen deposition in muscle biopsies was determined using the
standard periodic acid-Schiff (PAS) stain. Transverse (10 lm) TA
sections were obtained from snap-frozen tissue embedded in Tissue-
Tek O.C.T. compound (Sakura, Japan) on a cryostat (Leica CM
3050S, Germany) at 24°C. Freshly cut sections were briefly dried at
37°C for 30 min. Sections were then incubated for 10 min in periodic
acid 1% (Roth, Germany), followed by 30 min in Schiff’s reagent
(Roth, Germany) prior to a 5-min counterstain in Mayer’s solution
(Roth, Germany). After thorough washing, slides were dehydrated
with successive alcohol–toluene baths and mounted in Roti-Histokitt
(Roth, Germany). Microphotographs were obtained with an Eclipse
E800 microscope (Nikon, France). Counts were performed by an
investigator who was blinded to animal genotypes using National
Institutes of Health IMAGE version 1.62 software (USA).
The SDH staining was performed as follows: freshly dried cryo-
stat sections (14 lm) were incubated for 5 min at room temperature
(19–21°C) in a medium composed of 2 ml of nitroblue tetrazolium
stock solution (100 ml phosphate-buffered saline at pH 7.6, 6.5 mg
KCN, 185 mg EDTA, 100 mg NB), 0.2 ml succinate stock solution
(2.7 g sodium succinate, 20 ml distilled water), and 0.7 mg phen-
azine methosulfate. The sections were rinsed in acetone gradient,
cleared, and mounted in glycerin jelly. Microphotographs were
obtained with an Eclipse E800 microscope (Nikon). Muscle fiber
cross-sectional area of SDH-positive oxidative fibers and SDH-
negative glycolytic fibers was determined from digitized muscle
sections, using ImageJ software (http://imagej.nih.gov). The cross-
sectional area of 50 individual fibers/category and mouse was
determined from the number of pixels within manually outlined
fiber boundaries by an investigator who was blinded to genotypes
and treatment groups.
Statistical analysis
No previous statistical calculation was employed to determine
sample size. Instead, sample size in our experiments was chosen
based on usual procedures and best practices in the field (Ludolph
et al, 2010). Unless otherwise indicated, data are expressed as the
mean  SEM. For each figure, statistical tests are justified as appro-
priate. The significance of the difference between two groups was
determined with a two-tailed Student’s t-test. Multiple comparisons
were analyzed by analysis of variance (ANOVA) followed by
Fisher’s least significant difference (Fisher’s LSD) post hoc test. For
axotomy experiments, paired t-tests were performed to compare
between muscle ipsilateral and contralateral to the crush for each
mouse. Statistical tests used and the number of samples or animals
are specified in the respective figure legends. Differences with
P-values ≤ 0.05 were considered significant. Statistical analysis was
performed using Graphpad Prism version 6.0e (GraphPad, USA).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
Amyotrophic lateral sclerosis is the most common adult motor neuron
disorder characterized by motor neuron death and muscular atrophy,
which ultimately leads to death. To date, there is no efficient therapy
for this fatal disease. ALS has a very important metabolic component
as, in patients, energy deficit negatively impacts disease progression
and correlates with poorer prognosis. Muscle denervation in disease
progression seems to be a dynamic process of denervation and rein-
nervation that is different for the different muscle fiber types, with
the glycolytic muscle fibers being the first affected. In the present
work, we investigated potential metabolic mechanisms that may be
coupled to the muscle–nerve dialogue and NMJ stability and that
may account for the metabolic imbalance described in patients.
Results
The most important finding of our study in this neuromuscular
disease is an increase in endurance capacity during prolonged oxida-
tive exercise associated with a switch in fuel preference in glycolytic
muscle fibers toward lipid oxidation, prior to motor symptoms. The
increased expression of genes involved in lipid handling is accompa-
nied by a decrease in expression and activity of PFK1, the rate-
limiting enzyme of glycolysis. Glycolysis inhibition is a bottom-to-top
process, orchestrated by PDK4, a mitochondrial enzyme that blocks
the entry of pyruvate, the end product of glycolysis, into the TCA
cycle. The increase in lipid use is not accompanied by an increase in
mitochondrial biogenesis, but is associated with mitochondrial deficit
and increased oxidative stress. We further show that it is possible to
pharmacologically modulate this pathway and restore metabolic equi-
librium. By doing so, we were able to prevent denervation and muscu-
lar atrophy and improve metabolic profile in our ALS mouse model.
Impact
We show for the first time that muscle tissue suffers metabolic altera-
tions early in the course of disease development, alterations that influ-
ence the course of the pathology. These alterations are specific to
glycolytic muscle fibers and therefore can explain the sensitivity of glyco-
lytic fibers to atrophy and denervation. By exploring this mechanism, we
pinpoint the molecular components involved in these modifications. We
identify a potential therapeutic target in this pathway, which, if targeted,
may improve prognosis and quality of life for ALS patients.
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